• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

由ret酪氨酸激酶与环磷酸腺苷依赖性蛋白激酶A的调节亚基RIα融合形成的甲状腺肿瘤特异性转化序列的分子特征

Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI alpha of cyclic AMP-dependent protein kinase A.

作者信息

Bongarzone I, Monzini N, Borrello M G, Carcano C, Ferraresi G, Arighi E, Mondellini P, Della Porta G, Pierotti M A

机构信息

Division of Experimental Oncology A, Istituto Nazionale Tumori, Milan, Italy.

出版信息

Mol Cell Biol. 1993 Jan;13(1):358-66. doi: 10.1128/mcb.13.1.358-366.1993.

DOI:10.1128/mcb.13.1.358-366.1993
PMID:7678053
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC358915/
Abstract

The ret oncogene frequently has been found activated in papillary thyroid carcinomas. A previous characterization of ret activation revealed recombination of its tyrosine kinase domain and sequences derived from an uncharacterized locus (D10S170). The mechanism leading to this recombination was identified as a paracentric inversion of the long arm of chromosome 10, inv(10)(q11.2q21), with the breakpoints occurring where ret and D10S170 were mapped. To further characterize the activation of ret in papillary thyroid carcinomas, we have now isolated and sequenced a second type of ret oncogenic rearrangement not involving the D10S170 locus. The nucleotide sequence indicated that the transforming activity was created by the fusion of the ret tyrosine kinase domain with part of the RI alpha regulatory subunit of protein kinase A (PKA). This is the first example of an oncogenic activity involving a PKA gene. PKA is the main intracellular cyclic AMP receptor, and its RI alpha subunit gene is located on chromosome 17q. RI alpha-ret transcripts encode two isoforms of the chimeric protein (p76 and p81), which display constitutive tyrosine phosphorylation as well as a tyrosine kinase enzymatic activity. Under nonreducing conditions, both isoforms are found in a dimeric configuration because of both homo- and heterodimer formation. Thus, the in vivo activation of ret in human papillary thyroid carcinomas is provided by the fusion of its tyrosine kinase domain with different genes and can be mediated by different mechanisms of gene rearrangement.

摘要

RET原癌基因在甲状腺乳头状癌中经常被发现处于激活状态。先前对RET激活的特征描述显示,其酪氨酸激酶结构域与来自一个未鉴定基因座(D10S170)的序列发生了重组。导致这种重组的机制被确定为10号染色体长臂的臂间倒位,inv(10)(q11.2q21),断点发生在RET和D10S170被定位的位置。为了进一步表征RET在甲状腺乳头状癌中的激活情况,我们现在分离并测序了第二种不涉及D10S170基因座的RET致癌重排类型。核苷酸序列表明,转化活性是由RET酪氨酸激酶结构域与蛋白激酶A(PKA)的RIα调节亚基的一部分融合产生的。这是涉及PKA基因的致癌活性的首个例子。PKA是主要的细胞内环磷酸腺苷受体,其RIα亚基基因位于17号染色体q臂上。RIα-RET转录本编码嵌合蛋白的两种异构体(p76和p81),它们表现出组成型酪氨酸磷酸化以及酪氨酸激酶酶活性。在非还原条件下,由于同型和异型二聚体的形成,两种异构体都以二聚体形式存在。因此,人甲状腺乳头状癌中RET的体内激活是由其酪氨酸激酶结构域与不同基因的融合提供的,并且可以由不同的基因重排机制介导。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa3/358915/7b07d7a6ed2a/molcellb00013-0390-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa3/358915/480bb4cdcbf0/molcellb00013-0385-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa3/358915/95ed314e697c/molcellb00013-0390-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa3/358915/7b07d7a6ed2a/molcellb00013-0390-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa3/358915/480bb4cdcbf0/molcellb00013-0385-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa3/358915/95ed314e697c/molcellb00013-0390-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa3/358915/7b07d7a6ed2a/molcellb00013-0390-b.jpg

相似文献

1
Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI alpha of cyclic AMP-dependent protein kinase A.由ret酪氨酸激酶与环磷酸腺苷依赖性蛋白激酶A的调节亚基RIα融合形成的甲状腺肿瘤特异性转化序列的分子特征
Mol Cell Biol. 1993 Jan;13(1):358-66. doi: 10.1128/mcb.13.1.358-366.1993.
2
Frequent activation of ret protooncogene by fusion with a new activating gene in papillary thyroid carcinomas.
Cancer Res. 1994 Jun 1;54(11):2979-85.
3
Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC.10号染色体长臂上D10S170与RET并列并产生致癌序列RET/PTC的倒位特征分析
Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1616-20. doi: 10.1073/pnas.89.5.1616.
4
A t(10;17) translocation creates the RET/PTC2 chimeric transforming sequence in papillary thyroid carcinoma.
Genes Chromosomes Cancer. 1994 Apr;9(4):244-50. doi: 10.1002/gcc.2870090404.
5
Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma.RET/PTC3的分子特征;人类甲状腺乳头状癌中RET原癌基因的一种新的重排形式
Oncogene. 1994 Feb;9(2):509-16.
6
Identification of the product of two oncogenic rearranged forms of the RET proto-oncogene in papillary thyroid carcinomas.在甲状腺乳头状癌中鉴定RET原癌基因两种致癌重排形式的产物。
Oncogene. 1992 Nov;7(11):2189-94.
7
H4(D10S170), a gene frequently rearranged with RET in papillary thyroid carcinomas: functional characterization.H4(D10S170),一种在甲状腺乳头状癌中常与RET基因重排的基因:功能特征
Oncogene. 2004 Jan 8;23(1):109-21. doi: 10.1038/sj.onc.1206981.
8
Molecular and biochemical analysis of RET/PTC4, a novel oncogenic rearrangement between RET and ELE1 genes, in a post-Chernobyl papillary thyroid cancer.切尔诺贝利事故后发生的乳头状甲状腺癌中RET/PTC4(RET基因与ELE1基因之间一种新的致癌重排)的分子和生化分析
Oncogene. 1996 Sep 5;13(5):1093-7.
9
Breakpoint characterization of the ret/PTC oncogene in human papillary thyroid carcinoma.人甲状腺乳头状癌中ret/PTC癌基因的断点特征分析
Hum Mol Genet. 1995 Dec;4(12):2313-8. doi: 10.1093/hmg/4.12.2313.
10
The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma.Ret/ptc2的完整致癌活性取决于酪氨酸539,它是磷脂酶Cγ的一个对接位点。
Mol Cell Biol. 1996 May;16(5):2151-63. doi: 10.1128/MCB.16.5.2151.

引用本文的文献

1
Selpercatinib combination with the mitochondria-targeted antioxidant MitoQ effectively suppresses RET-mutant thyroid cancer.塞尔帕替尼与线粒体靶向抗氧化剂MitoQ联合使用可有效抑制RET突变型甲状腺癌。
NPJ Precis Oncol. 2024 Feb 20;8(1):39. doi: 10.1038/s41698-024-00536-7.
2
RET fusion genes in pediatric and adult thyroid carcinomas: cohort characteristics and prognosis.RET 融合基因在儿童和成人甲状腺癌中的作用:队列特征和预后。
Endocr Relat Cancer. 2023 Oct 26;30(12). doi: 10.1530/ERC-23-0117. Print 2023 Dec 1.
3
RET signaling pathway and RET inhibitors in human cancer.

本文引用的文献

1
A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity.一种将DNA限制性内切酶片段放射性标记至高比活度的技术。
Anal Biochem. 1983 Jul 1;132(1):6-13. doi: 10.1016/0003-2697(83)90418-9.
2
Interchain disulfide bonding in the regulatory subunit of cAMP-dependent protein kinase I.环磷酸腺苷依赖性蛋白激酶I调节亚基中的链间二硫键结合
J Biol Chem. 1982 Mar 10;257(5):2287-93.
3
Phosphotyrosine-containing proteins isolated by affinity chromatography with antibodies to a synthetic hapten.通过与合成半抗原抗体进行亲和层析分离得到的含磷酸酪氨酸的蛋白质。
人类癌症中的RET信号通路与RET抑制剂
Front Oncol. 2022 Jul 25;12:932353. doi: 10.3389/fonc.2022.932353. eCollection 2022.
4
RET kinase inhibitors for -altered thyroid cancers.用于RET基因改变的甲状腺癌的RET激酶抑制剂。
Ther Adv Med Oncol. 2022 Jun 21;14:17588359221101691. doi: 10.1177/17588359221101691. eCollection 2022.
5
The Genomic Landscape of Thyroid Cancer Tumourigenesis and Implications for Immunotherapy.甲状腺癌肿瘤发生的基因组全景及其对免疫治疗的影响。
Cells. 2021 May 1;10(5):1082. doi: 10.3390/cells10051082.
6
Ret signaling in ureteric bud epithelial cells controls cell movements, cell clustering and bud formation.Ret 信号在输尿管芽上皮细胞中控制细胞运动、细胞聚集和芽形成。
Development. 2021 May 1;148(9). doi: 10.1242/dev.199386. Epub 2021 Apr 29.
7
Kinase gene fusions: roles and therapeutic value in progressive and refractory papillary thyroid cancer.激酶基因融合:在进展性和难治性甲状腺滤泡状癌中的作用和治疗价值。
J Cancer Res Clin Oncol. 2021 Feb;147(2):323-337. doi: 10.1007/s00432-020-03491-5. Epub 2021 Jan 2.
8
RET Gene Fusions in Malignancies of the Thyroid and Other Tissues.RET 基因融合在甲状腺和其他组织恶性肿瘤中的作用。
Genes (Basel). 2020 Apr 15;11(4):424. doi: 10.3390/genes11040424.
9
Discovery Stories of RET Fusions in Lung Cancer: A Mini-Review.肺癌中RET融合的发现故事:一篇综述短文
Front Physiol. 2019 Mar 19;10:216. doi: 10.3389/fphys.2019.00216. eCollection 2019.
10
Thyroid cancers of follicular origin in a genomic light: in-depth overview of common and unique molecular marker candidates.滤泡性起源的甲状腺癌的基因组视角:常见和独特的分子标志物候选物的深入概述。
Mol Cancer. 2018 Aug 8;17(1):116. doi: 10.1186/s12943-018-0866-1.
Nature. 1981 Dec 17;294(5842):654-6. doi: 10.1038/294654a0.
4
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.在噬菌体T4头部组装过程中结构蛋白的切割
Nature. 1970 Aug 15;227(5259):680-5. doi: 10.1038/227680a0.
5
Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains.编码具有两个潜在跨膜结构域的酪氨酸激酶的原癌基因ret的克隆与表达。
Oncogene. 1988 Nov;3(5):571-8.
6
A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences.一种由截短的原肌球蛋白和蛋白酪氨酸激酶序列融合形成的人类癌基因。
Nature. 1986;319(6056):743-8. doi: 10.1038/319743a0.
7
Activation of the ret-II oncogene without a sequence encoding a transmembrane domain and transforming activity of two ret-II oncogene products differing in carboxy-termini due to alternative splicing.ret-II癌基因的激活,该基因没有编码跨膜结构域的序列,以及由于可变剪接导致羧基末端不同的两种ret-II癌基因产物的转化活性。
Oncogene. 1989 Jun;4(6):789-94.
8
Detection and purification of inhibin using antisera generated against synthetic peptide fragments.使用针对合成肽片段产生的抗血清检测和纯化抑制素。
Methods Enzymol. 1989;168:588-617. doi: 10.1016/0076-6879(89)68044-5.
9
High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma.人乳头状甲状腺癌中酪氨酸激酶癌基因的高频激活
Oncogene. 1989 Dec;4(12):1457-62.
10
The cyclic AMP-mediated stimulation of cell proliferation.环磷酸腺苷介导的细胞增殖刺激。
Trends Biochem Sci. 1989 Feb;14(2):67-71. doi: 10.1016/0968-0004(89)90046-7.